BRPI0910259A2 - métodos de tratamento de inflamação - Google Patents

métodos de tratamento de inflamação

Info

Publication number: BRPI0910259A2
Authority: BR; Brazil
Prior art keywords: treatment methods; inflammation treatment; inflammation; methods; treatment
Prior art date: 2008-03-20

Application number

BRPI0910259A

Other languages

English (en)

Inventor

Alma Zernecke

Benedikt Vollrath

Christian Weber

Joshua Robert Schultz

Jürgen Bernhagen

Original Assignee

Carolus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-20

Filing date

2009-03-20

Publication date

2015-12-01

2009-03-20 Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc

2015-12-01 Publication of BRPI0910259A2 publication Critical patent/BRPI0910259A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Oncology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Vascular Medicine (AREA)
Biochemistry (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)

BRPI0910259A 2008-03-20 2009-03-20 métodos de tratamento de inflamação BRPI0910259A2 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US3838108P	2008-03-20	2008-03-20
US3937108P	2008-03-25	2008-03-25
US4580708P	2008-04-17	2008-04-17
US12109508P	2008-12-09	2008-12-09
PCT/US2009/037887 WO2009117710A2 (en)	2008-03-20	2009-03-20	Methods of treating inflammation

Publications (1)

Publication Number	Publication Date
BRPI0910259A2 true BRPI0910259A2 (pt)	2015-12-01

Family

ID=41091567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0910259A BRPI0910259A2 (pt)	2008-03-20	2009-03-20	métodos de tratamento de inflamação

Country Status (14)

Country	Link
US (2)	US20110262386A1 (pt)
EP (2)	EP2254597A4 (pt)
JP (2)	JP2011515416A (pt)
KR (1)	KR20110014141A (pt)
CN (2)	CN102088993A (pt)
AU (2)	AU2009225389A1 (pt)
BR (1)	BRPI0910259A2 (pt)
CA (2)	CA2717071A1 (pt)
CO (1)	CO6300848A2 (pt)
EA (1)	EA201001529A1 (pt)
IL (1)	IL207752A0 (pt)
MX (1)	MX2010010198A (pt)
NZ (1)	NZ588033A (pt)
WO (2)	WO2009117706A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110262386A1 (en) *	2008-03-20	2011-10-27	Carolus Therpeutics, Inc.	Methods of treating inflammation
CA2716628A1 (en) *	2008-03-24	2009-10-01	Carolus Therapeutics, Inc.	Methods and compositions for treating atherosclerosis and related conditions
WO2010056910A2 (en) *	2008-11-12	2010-05-20	Carolus Therapeutics, Inc.	Methods of treating cardiovascular disorders
KR20120105429A (ko) *	2009-09-23	2012-09-25	카롤러스 테라퓨틱스, 인코포레이티드	염증 치료 방법
EP2308485A1 (en) *	2009-10-06	2011-04-13	Dompé S.p.a.	Sulfonamides for the prevention of diabetes
EP2308484A1 (en)	2009-10-06	2011-04-13	Dompé S.p.a.	Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
WO2012125680A1 (en)	2011-03-16	2012-09-20	Novartis Ag	Methods of treating vasculitis using an il-17 binding molecule
EP3354640A3 (en) *	2011-04-13	2018-10-31	Innovimmune Biotherapeutics, Inc.	Mif inhibitors and their uses
TWI407964B (zh) *	2011-05-10	2013-09-11	Univ Fu Jen Catholic	干擾性核糖核酸用於治療或減緩疼痛之用途
US11492383B2 (en)	2011-06-24	2022-11-08	Stephen D. Gillies	Light chain immunoglobulin fusion proteins and methods of use thereof
CA2831154C (en)	2011-06-30	2021-01-12	Dignity Health	Use of pertussis toxin as a therapeutic agent
US10596233B2 (en)	2011-06-30	2020-03-24	Dignity Health	Use of pertussis toxin as a therapeutic agent
US9238689B2 (en)	2011-07-15	2016-01-19	Morpho Sys AG	Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
CN102357249A (zh) *	2011-10-26	2012-02-22	广州赫尔氏药物开发有限公司	能够抑制耐药性结核杆菌的药物
CA3095012C (en)	2012-05-01	2023-02-07	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
US10561676B2 (en) *	2013-08-02	2020-02-18	Syntrix Biosystems Inc.	Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en)	2013-08-02	2018-08-14	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists
WO2015051330A1 (en)	2013-10-03	2015-04-09	Oregon Health & Science University	RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II α1 DOMAINS
JP6863897B2 (ja) *	2015-01-09	2021-04-21	アダルタ・リミテッド	Ｃｘｃｒ４結合分子
TW201718851A (zh) *	2015-09-18	2017-06-01	通用醫院公司	具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
WO2017106328A1 (en) *	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methods for treating cancer
EP3389652B1 (en)	2015-12-14	2022-09-28	X4 Pharmaceuticals, Inc.	Methods for treating cancer
MX2018010946A (es)	2016-03-11	2019-05-23	Ardea Biosciences Inc	Inhibidores de cxcr-2 para tratamiento de trastornos de artropatia por cristales.
KR102645432B1 (ko) *	2016-03-28	2024-03-11	(주)아모레퍼시픽	피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법
CN109153722A (zh)	2016-04-08	2019-01-04	X4 制药有限公司	用于治疗癌症的方法
US20190134231A1 (en) *	2016-04-21	2019-05-09	The Board Of Regents Of The University Of Texas System	Methods and compositions for detecting aneurysms
CN116903741A (zh)	2016-06-20	2023-10-20	科马布有限公司	特异性结合于pd-l1的抗体或其抗原结合片段及其用途
WO2017223229A1 (en)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
CN109562106B (zh)	2016-06-21	2023-03-21	X4 制药有限公司	Cxcr4抑制剂及其用途
JP6994767B2 (ja)	2016-06-21	2022-01-14	エックス４ファーマシューティカルズ，インコーポレイテッド	Ｃｘｃｒ４阻害剤およびその使用
AU2017339942B2 (en)	2016-10-03	2023-06-29	Dompe Farmaceutici S.P.A.	Prevention and treatment of diabetic nephropathy
CN108355133A (zh) *	2017-01-26	2018-08-03	中国医学科学院阜外医院	靶向cxcr7的药物组合物和方法
CN107964045B (zh) *	2017-12-18	2021-04-23	南京医科大学	一种人鼠嵌合抗CXCR2全分子IgG及其应用
BR112020020930A2 (pt)	2018-04-11	2021-03-02	Ohio State Innovation Foundation	composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
CA3102032A1 (en)	2018-06-05	2019-12-12	Anji Pharma (Us) Llc	Compositions and methods for treating pancreatitis
JP2021526820A (ja) *	2018-06-07	2021-10-11	オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
MX2021007604A (es) *	2018-12-26	2021-08-11	Colgate Palmolive Co	Biomarcadores de desregulacion de neutrofilos como diagnostico de gingivitis.
CN110133306B (zh) *	2019-05-09	2023-04-07	北京勤邦生物技术有限公司	检测西马特罗的酶联免疫试剂盒及其应用
IL296338A (en) *	2020-03-11	2022-11-01	Biolinerx Ltd	cxcr4 inhibitor for the treatment of acute respiratory syndrome and viral infections
US20210338626A1 (en) *	2020-04-28	2021-11-04	Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch	Methods for treating or preventing a viral infection or inhibiting viral replication
EP4320445A1 (en)	2021-04-08	2024-02-14	Joslin Diabetes Center, Inc.	Methods of diagnosing and predicting renal decline
KR102561554B1 (ko) *	2021-04-14	2023-07-28	부산대학교 산학협력단	치주질환 진단용 바이오마커 조성물, 치주질환 치료 효용성 평가용 바이오마커 조성물 및 이를 이용한 진단키트
WO2023150294A2 (en) *	2022-02-04	2023-08-10	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Methods of detecting and treating cerebral aneurysms

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6030615A (en) *	1993-05-17	2000-02-29	The Picower Institute For Medical Research	Combination method for treating diseases caused by cytokine-mediated toxicity
EP1741779A3 (en) *	1993-05-17	2010-03-24	The Picower Institute For Medical Research	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity
US20070072861A1 (en) *	2000-03-27	2007-03-29	Barbara Roniker	Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
JP2004531237A (ja) *	2001-01-12	2004-10-14	サイトカイン・ファーマサイエンシズ・インコーポレーテッド	マクロファージ遊走阻止因子による細胞障害性リンパ球応答の調節を調整するための方法及び組成物
WO2003047622A1 (fr) *	2001-11-30	2003-06-12	Jun Nishihira	Remedes pour la sclerose en plaques
JP2003226653A (ja) *	2001-11-30	2003-08-12	Jun Nishihira	多発性硬化症治療剤
US6656168B2 (en) *	2001-12-18	2003-12-02	Kimberly-Clark Worldwide, Inc.	Feminine care product with discrete areas of a skin wellness additive
US20040009149A1 (en) *	2002-02-27	2004-01-15	Altman John D.	Multimeric binding complexes
EP1483294B2 (en) *	2002-03-01	2019-10-30	Immunomedics, Inc.	Internalizing anti-cd74 antibodies and methods of use
US20060233877A1 (en) *	2002-11-25	2006-10-19	Jallal Messadek	Betaine compositions
TW200418829A (en) *	2003-02-14	2004-10-01	Avanir Pharmaceutics	Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20050202010A1 (en) *	2003-08-29	2005-09-15	Giroir Brett P.	Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
WO2005065328A2 (en) *	2003-12-30	2005-07-21	The United States Of America, As Represented By The Department Of Veterans Affairs	Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
WO2006105666A1 (en) *	2005-04-06	2006-10-12	Queen's University At Kingston	Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
WO2007138961A1 (ja) *	2006-05-29	2007-12-06	Redox Bioscience Inc.	マクロファージ遊走阻止因子によって引き起こされる障害の予防乃至治療剤
US20110262386A1 (en) *	2008-03-20	2011-10-27	Carolus Therpeutics, Inc.	Methods of treating inflammation
CA2716628A1 (en) *	2008-03-24	2009-10-01	Carolus Therapeutics, Inc.	Methods and compositions for treating atherosclerosis and related conditions
WO2010056910A2 (en) *	2008-11-12	2010-05-20	Carolus Therapeutics, Inc.	Methods of treating cardiovascular disorders
WO2010065491A2 (en) *	2008-12-01	2010-06-10	Carolus Therapeutics, Inc.	Methods of treating inflammatory disorders

2009
- 2009-03-20 US US12/918,964 patent/US20110262386A1/en not_active Abandoned
- 2009-03-20 EA EA201001529A patent/EA201001529A1/ru unknown
- 2009-03-20 CN CN2009801093284A patent/CN102088993A/zh active Pending
- 2009-03-20 KR KR1020107023480A patent/KR20110014141A/ko not_active Application Discontinuation
- 2009-03-20 EP EP09722541A patent/EP2254597A4/en not_active Withdrawn
- 2009-03-20 AU AU2009225389A patent/AU2009225389A1/en not_active Abandoned
- 2009-03-20 US US12/918,968 patent/US20110044988A1/en not_active Abandoned
- 2009-03-20 BR BRPI0910259A patent/BRPI0910259A2/pt not_active IP Right Cessation
- 2009-03-20 CA CA2717071A patent/CA2717071A1/en not_active Abandoned
- 2009-03-20 WO PCT/US2009/037883 patent/WO2009117706A2/en active Application Filing
- 2009-03-20 CA CA2717365A patent/CA2717365A1/en not_active Abandoned
- 2009-03-20 WO PCT/US2009/037887 patent/WO2009117710A2/en active Application Filing
- 2009-03-20 NZ NZ588033A patent/NZ588033A/xx not_active IP Right Cessation
- 2009-03-20 JP JP2011501000A patent/JP2011515416A/ja active Pending
- 2009-03-20 CN CN200980109905XA patent/CN102046199A/zh active Pending
- 2009-03-20 JP JP2011501003A patent/JP2011526244A/ja active Pending
- 2009-03-20 AU AU2009225385A patent/AU2009225385A1/en not_active Abandoned
- 2009-03-20 MX MX2010010198A patent/MX2010010198A/es active IP Right Grant
- 2009-03-20 EP EP09721240A patent/EP2252318A4/en not_active Withdrawn
2010
- 2010-08-23 IL IL207752A patent/IL207752A0/en unknown
- 2010-09-20 CO CO10116141A patent/CO6300848A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN102088993A (zh)	2011-06-08
IL207752A0 (en)	2010-12-30
US20110262386A1 (en)	2011-10-27
CA2717071A1 (en)	2009-09-24
CO6300848A2 (es)	2011-07-21
AU2009225389A1 (en)	2009-09-24
WO2009117710A3 (en)	2010-01-21
JP2011526244A (ja)	2011-10-06
CA2717365A1 (en)	2009-09-24
EP2254597A2 (en)	2010-12-01
EP2254597A4 (en)	2012-04-18
NZ588033A (en)	2012-11-30
EA201001529A1 (ru)	2011-06-30
KR20110014141A (ko)	2011-02-10
AU2009225385A1 (en)	2009-09-24
EP2252318A2 (en)	2010-11-24
WO2009117706A2 (en)	2009-09-24
MX2010010198A (es)	2010-12-21
JP2011515416A (ja)	2011-05-19
US20110044988A1 (en)	2011-02-24
CN102046199A (zh)	2011-05-04
EP2252318A4 (en)	2012-04-18
WO2009117710A2 (en)	2009-09-24
WO2009117706A3 (en)	2010-01-21

Publication	Publication Date	Title
BRPI0910259A2 (pt)	2015-12-01	métodos de tratamento de inflamação
BRPI0910854A2 (pt)	2015-10-06	métodos de tratamento
BRPI0917575A2 (pt)	2019-09-24	métodos de tratamento de talassemia
LTC2330892I2 (lt)	2018-06-11	Gydymo būdai panaudojant vaistus - amoniako gaudykles
BRPI0810206A2 (pt)	2014-10-21	Método de tratar câncer
BR112012005594A2 (pt)	2015-09-08	tratamento de câncer
BRPI0921327A2 (pt)	2015-08-25	Combinação de herbicida-protetor
BRPI0914841A2 (pt)	2015-10-27	aparelho de massagem
IT1391555B1 (it)	2012-01-11	Apparato trattamento extracorporeo sangue
DK2330887T3 (da)	2013-05-21	Behandlingsindretning
FIC20240018I1 (fi)	2024-06-04	Vamoroloni
DK2361116T3 (da)	2019-05-20	Bestrålingsindretning
BRPI0919127A2 (pt)	2015-12-08	métodos para tratamento de água
DK2837348T3 (da)	2020-05-04	Kryokirurgiske fremgangsmåder
BRPI0911625A2 (pt)	2015-08-04	Métodos
BRPI0821652A2 (pt)	2017-04-04	tratamento de biocombustíveis
DK2173831T3 (da)	2012-09-17	Brøndbehandling
BRPI0920743A2 (pt)	2016-09-20	ribonucleases terapeuticas
DE112009001577A5 (de)	2012-02-23	Verstellpumpe
BRPI0916079A2 (pt)	2015-11-10	tratamento de água marinha residual
BRPI1010516A2 (pt)	2015-08-25	Métodos de tratamento de edema relacionados à isquemia-reperfusão
BRPI0922728A2 (pt)	2019-09-24	combinação de herbicida-antídoto
BRPI1007543A2 (pt)	2016-02-16	tratamento de psoríase
IT1392349B1 (it)	2012-02-28	Dispositivo massaggiatore
DK2376121T4 (da)	2021-08-16	Slidgigtbehandling

Legal Events

Date	Code	Title	Description
2016-07-19	B25G	Requested change of headquarter approved	Owner name: CAROLUS THERAPEUTICS, INC. (US)
2016-09-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-12-20	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.